Oral Celastrol Micelles Forming High‐Density Lipoprotein Corona Targeting Hepatocytes for MASLD Treatment
Advanced Science · 2025-12 · 12 (45)
DOI: 10.1002/advs.202500854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 23.09.2025. Verfasst von Chang Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China. Hauptthemen laut MEDLINE: Pentacyclic Triterpenes, Hepatocytes, Lipoproteins, HDL, Fatty Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, the Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform, the Construction Fund of Key Medical Disciplines of Hangzhou.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a multifactorial hepatic manifestation of metabolic syndrome, such as aberrant lipid accumulation. Celastrol (CEL), a potent leptin sensitizer, has been studied for the treatment of MASLD; however, its clinical application is hindered by its low oral bioavailabilities and high toxicities. Herein, CEL is encapsulated into the micelles of poly[2‐(N‐oxide‐N,N‐diethylamino)ethyl methacrylate]‐block‐poly(ε‐caprolactone) (OPDEA‐PCL), whose shell is capable of fast penetrating mucus due to its protein‐non‐fouling and rapid transcytosis induction as a result of phospholipid‐binding characteristic. After oral administration, OPDEA‐PCL/CEL micelles sequentially permeated through the gastrointestinal barriers into the blood. Notably, it is found that OPDEA‐PCL/CEL specifically captured high‐density lipoproteins (HDL) in plasma, forming an HDL corona actively targeting the hepatocytes, delivering a high concentration of CEL. In the MASLD mouse model, oral administration of OPDEA‐PCL/CEL effectively alleviated hepatic lipid accumulation, lessened hepatic inflammation, and mitigated the toxicities of CEL with therapeutic efficacy superior to free CEL and PEG‐PCL/CEL and even the current clinical simvastatin. Therefore, the OPDEA‐PCL may be a promising oral CEL delivery system for treating MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China.
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, China.
- Zhejiang University School of Medicine, Hangzhou, 310058, China.
- Key Laboratory of Smart Biomaterials of Zhejiang Province and Key Laboratory of Biomass Chemical Engineering of the Ministry of Education of China, College of Chemical and Biological Engineering, Zhejiang University, Ha…
- School of Clinical Medicine, Hangzhou Medical College, Hangzhou, 310053, China.
- Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, China.
Förderung
- National Key Research and Development Program of China
- the Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform
- the Construction Fund of Key Medical Disciplines of Hangzhou
- Zhejiang Provincial Medical and Health Technology Project
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Xu, C., Zhu, H., Wang, K., Hu, H., Wei, X., Xu, D., Zhang, J., Liu, Y., Chen, J., Shen, Y., Qiu, N., & Xu, X. (2025). Oral Celastrol Micelles Forming High‐Density Lipoprotein Corona Targeting Hepatocytes for MASLD Treatment. Advanced Science, 12(45). https://doi.org/10.1002/advs.202500854
Vancouver
Xu C, Zhu H, Wang K, Hu H, Wei X, Xu D, et al. Oral Celastrol Micelles Forming High‐Density Lipoprotein Corona Targeting Hepatocytes for MASLD Treatment. Advanced Science. 2025;12(45). doi:10.1002/advs.202500854
BibTeX
@article{Xu2025,
author = {Xu, Chang and Zhu, Haoru and Wang, Kai and Hu, Haitao and Wei, Xuyong and Xu, Dongdong and Zhang, Jing and Liu, Yanpeng and Chen, Jun and Shen, Youqing and Qiu, Nasha and Xu, Xiao},
title = {Oral Celastrol Micelles Forming High‐Density Lipoprotein Corona Targeting Hepatocytes for MASLD Treatment},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {45},
doi = {10.1002/advs.202500854}
}
EUVIMED